Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported the Phase I results from a randomized, multi-center, Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide and lenalidomide (VcDCR) in patients with previously untreated multiple myeloma (MM). The preliminary analysis of the safety data showed that the combination of four drugs was generally well tolerated in patients who had received no prior therapies and response rates were encouraging. These data were presented at the 50th Annual Meeting of the American Society of Hematology (ASH), held December 5-9, 2008 in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

This trial, called EVOLUTION(1), builds on positive results from previous studies of VELCADE based combinations in this setting. The presentation reported the first clinical data with the novel four-drug combination. The safety results allow the trial to proceed to Phase II, which will randomize patients to receive VcDR, VcDC or VcDCR.

Results from the 25 patients treated in this trial with VcDCR for a median of four cycles (range: 2-11 cycles), which were presented by Shaji Kumar, M.D., Mayo Clinic, showed:

-- The maximum tolerated dose of cyclophosphamide in the VcDCR regimen was not reached. The recommended doses for the Phase II portion of the trial include 500 mg/m(2) of cyclophosphamide, the highest planned dose, 1.3 mg/m(2) of VELCADE, 40 mg of dexamethasone and 15 mg of lenalidomide.

-- The only two dose-limiting toxicities reported were febrile neutropenia and reactivation of the Herpes Zoster virus infection.

-- The overall rate of serious adverse events (AEs) was 40 percent. The most common treatment-emergent AEs were constipation (64 percent), fatigue
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Calif. , Aug. 27, 2015 DURECT ... is scheduled to present at three upcoming healthcare conferences.  ... President and CEO, will present at the Rodman & ... a.m. Eastern time. The conference is being held at ... City . A live audio webcast of the ...
(Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
(Date:8/27/2015)... , Aug. 27, 2015  MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, ... and corrected the multiple inaccuracies in the press ... regarding the recent rulings from the Patent Trial ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4
... CHICAGO, June 5, 2011 Nektar Therapeutics (Nasdaq: ... subpopulation of patients in a Phase 2 clinical study ...  A total of 33 women in the study with ... evaluable for response rate using either RECIST 1.0 criteria ...
... Health, Inc. (Nasdaq: GHDX ) today announced ... Society of Clinical Oncology (ASCO) Annual Meeting, including a ... Onco type DX® colon cancer Recurrence Score® (RS) ... II colon cancer.  The company also will present positive ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
(Date:8/27/2015)... Manistee, Michigan (PRWEB) , ... August 27, 2015 , ... ... Rehabilitation returned for the second year as sponsor of the “Music With A Mission” ... to raise money for music education programs in the underfunded school districts of Mendon ...
(Date:8/27/2015)... ... 2015 , ... Dr. Jennifer Arnold, co-star of “The Little Couple” and a ... 3rd Annual MPN Heroes™ recognition event on Friday, Dec. 4, prior to the ... eight heroes who have made significant contributions in the field of rare blood cancers ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast is pleased to announce ... in San Jose, CA. The first event dedicated to finding alternative solutions ... exists where battery development and energy storage innovation are concerned. Product developers, ...
(Date:8/27/2015)... Mirada, CA (PRWEB) , ... August 27, 2015 , ... ... Agency, into its La Tijera Clinic in Los Angeles. Licensed to practice Chinese Needle ... an emphasis on neuromuscular injuries and diseases. Dr. Priebe also practices in Healthpointe’s La ...
(Date:8/27/2015)... ... , ... More destinations and stores are becoming pet-friendly, making the family companion ... some tips to help your whole family travel safely and comfortably. , According to ... year. Amica is sharing the following tips from the American Society for the Prevention ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2
... YMCA of the USA (Y-USA) has,received a $6.8 ... (RWJF),to expand an innovative national initiative that helps ... Healthier Communities (PHC),encourages policy and environmental change in ... increased physical activity and,improved nutrition. The public ...
... FACP, FACEP (E), Executive Director, American Public Health Association , ... "At a time when national interest in reforming the health ... (APHA) applauds President-elect Obama for prioritizing health reform and selecting ... and Human Services, as well as the new White House ...
... Dec 11 The U.S. government, through the U.S. ... million and has deployed a Disaster Assistance Response Team (DART) ... assistance is in addition to more than $4.6 million for ... implementing in Zimbabwe. , , ...
... an electrical problem , , THURSDAY, Dec. 11 (HealthDay News) -- ... has been identified by U.S. researchers. , ... lead to new drugs and new ways of detecting the ... fibrillation is characterized by uncoordinated, chaotic and rapid beating of ...
... the age of 100 and never looking a day over 60 is ... And now, this information is available to everyone absolutely free. ... ... Natural Health News Report is offering a free download to the popular ...
... MONICA, Calif., Dec. 11 Less than 15% of U.S. ... insurers requiring every American to provide proof of private health ... a new poll. The poll, conducted by Consumer Watchdog, ... favor requiring a return on taxpayer-funded research that leads to ...
Cached Medicine News:Health News:YMCA of the USA Expands Healthy Communities Initiatives With $6.8 Million Grant from the Robert Wood Johnson Foundation 2Health News:USAID Provides Additional $6.2M for Zimbabwe Cholera Outbreak 2Health News: Anti-Aging Miracle Physicians Have Been Waiting for is Finally Here : Free Book Available From Natural Health News Report Reveals the Secret to Staying Young 2Health News:New Poll Warns Daschle, Obama: Mandatory Health Insurance Big Loser With Public; Voters Want Return on Stem Cell Research 2Health News:New Poll Warns Daschle, Obama: Mandatory Health Insurance Big Loser With Public; Voters Want Return on Stem Cell Research 3
... Certified by an independent laboratory ... of Federal Standard 209E. Ergonomic ... fatique and back injuries. Clean ... requirements. Static-control chairs feature dissipative ...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... Vibratome Roto-Shake Genie is an all-in-one ... It performs five different mixing motions: ... rotating/rolling, as well as a combination ... precision-engineered moving portion of the Vibraotme ...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Medicine Products: